Chinfloxacin hydrochloride inhibits HERG potassium channel at open state

Yaoxue Xuebao

Volumn 45, Issue 12, 2010, Pages 1491-1496

  Zhang, Xiang Mei ^a   Zhu, Zhong Hua ^a   Sun, Xiao Li ^a   Guo, Jia ^a   Zhao, Zhong Zhong ^a   Zhang, Zhao ^a  

^a NANJING NORMAL UNIVERSITY   (China)

Author keywords

Chinfloxacin hydrochloride; Fluoroquinolone; HERG potassium channel

Indexed keywords

CHINFLOXACIN HYDROCHLORIDE; GREEN FLUORESCENT PROTEIN; MOXIFLOXACIN; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; POTASSIUM ION; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; IC 50; PLASMID;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; FLUOROQUINOLONES; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MOLECULAR STRUCTURE; PATCH-CLAMP TECHNIQUES; POTASSIUM; QUINOLINES; TIME FACTORS; TRANSFECTION;

EID: 78650653453     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia [J]. Nature, 2006, 440: 463-469.
2. Sanguinetti MC, Chen J, Fernandez D, et al. Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs [J]. Novartis Found Symp, 2005, 266: 159-166; discussion 166-170.
3. Mitcheson JS. hERG potassium channels and the structural basis of drug-induced arrhythmias [J]. Chem Res Toxicol, 2008,21: 1005-1010.
4. Stansfeld P.J. Gedeck P. Gosling M. Cox B. Mitcheson J.S. Sutcliffe M.J. Drug block of the hERG potassium channel: Insight from modeling Proteins: Structure, Function and Genetics 2007 68 2 568-580 DOI 10.1002/prot.21400 [4] Stansfeld PJ, Gedeck P, Gosling M, et al. Drug block of the hERG potassium channel: insight from modeling [J]. Proteins, 2007, 68: 568-580. (Pubitemid 46981949)
5. + channel blockade by the fluoroquinolone antibiotic moxifloxacin [J]. Br J Pharmacol, 2006,147: 905-916.
6. Su Z, Limberis J, Souers A, et al. Electrophysiologic characterization of a novel hERG channel activator [J]. Biochem Pharmacol, 2009, 77: 1383-1390.
7. Zhou Z. Gong Q. Ye B. Fan Z. Makielski J.C. Robertson G.A. January C.T. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature Biophysical Journal 1998 74 1 230-241 [7] Zhou Z, Gong Q, Ye B, et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature [J]. Biophys J, 1998, 74: 230-241. (Pubitemid 28041752)
8. Zitron E, Karle CA, Wendt-Nordahl G, et al. Bertosamil blocks HERG potassium channels in their open and inactivated states [J]. Br J Pharmacol, 2002, 137: 221-228.
9. Yang P. Kanki H. Drolet B. Yang T. Wei J. Viswanathan P.C. Hohnloser S.H. Shimizu W. Schwartz P.J. Stanton M. Murray K.T. Norris K. George A.L. Jr. Roden D.M. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes Circulation 2002 105 16 1943-1948 DOI 10.1161/01.CIR. 0000014448.19052.4C [9] Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes [J]. Circulation, 2002, 105: 1943-1948. (Pubitemid 34437622)
10. + channel HERG [J]. Mol Pharmacol, 2001, 59: 122-126.
11. Ducroq J, Moha ou Maati H, Guilbot S, et al. Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks) [J]. Br J Pharmacol, 2010, 159: 93-101.
12. Redfern W.S. Carlsson L. Davis A.S. Lynch W.G. MacKenzie I. Palethorpe S. Siegl P.K.S. Strang I. Sullivan A.T. Wallis R. Camm A.J. Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development Cardiovascular Research 2003 58 1 32-45 DOI 10.1016/S0008-6363(02)00846-5 [12] Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development [J]. Cardiovasc Res, 2003, 58: 32-45. (Pubitemid 36351620)